ALPI and irritable bowel syndrome: In light of accumulated evidence presented in this review and the fact that the human recombinant form of IAP (recAP) has been developed and this recombinant form of IAP has been safely administered to humans without any adverse effects, we conclude that IAP may represent a potential therapeutic agent to improve outcomes of inflammatory diseases driven by gut barrier dysfunction such as IBD.